https://www.roche.com/investors/updates/inv-update-2022-12-16
CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
The positive CHMP opinion is based on the results of the HAVEN 6 study, which demonstrated effective bleed control and a favourable safety profile of Hemlibra...
expansion of euchmprecommendslabelhemlibra